$GH

Kalia Kumud sold $157K of GH

Kalia Kumud (Chief Information Officer) sold 1,200 shares of Guardant Health, Inc. (GH) at an average of $130.97 ($130.86–$131.08, $0.16M total) across 2 trades over 2026-06-10 to 2026-06-15.

Original reporting
SEC EDGAR · Kalia Kumud
Published Jun 30, 2026, 9:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 30, 2026, 9:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GH
Neutral
high confidence
Mentioned
$GH
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHNeutralLow
01

Why it matters

The newest information is the specific open-market sale details (shares, price range, total value, and post-transaction holdings) filed on 2026-06-30 for trades executed mid-June.

02

Market read

This provides a fresh datapoint on insider behavior, but it is not accompanied by guidance, earnings, or operational developments.

03

What to watch

No 10b5-1 plan is stated; traders may still treat the absence of a plan as marginally more informative, but the disclosed size remains small.

Relevance 4/10Novelty 6/10Timing: Filed after-hours on 2026-06-30; reflects sales executed 2026-06-10 to 2026-06-15.

Background

The article is a SEC Form 4 insider transaction disclosure for Guardant Health, Inc. (GH).

Company-level read

Ticker impact

$GHNeutralHigh confidence
Context

Guardant Health CIO Kalia Kumud filed an open-market sale of 1,200 shares at ~$130.97 (total ~$157k) on June 10–15, 2026.

Expected impact

Low likelihood of a sustained price move; any impact would be short-lived unless accompanied by other company-specific news.

Evidence & confidence

This is a Form 4 insider transaction with modest dollar value and no 10b5-1 plan stated; the filing itself is new, but it does not disclose new operating/financial information.

Market effects

Minimal; insider selling at a single healthcare/diagnostics name typically does not reset sector expectations.

None indicated; US-listed Form 4 filing with small transaction value.

None indicated; no cross-border deal/regulatory action mentioned.

Counterpoint

The sale could be unrelated to company outlook (tax/portfolio rebalancing), especially since the filing does not indicate distress or a planned program.

Key entities

  • Guardant Health, Inc.

    US-listed company whose insider transaction was disclosed via Form 4.

  • Kalia Kumud

    Chief Information Officer who sold 1,200 shares in two open-market trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GHMed

Guardant Health stock hits 52-week high at 176.68 USD

Guardant Health Inc. (GH) hit a 52-week high of $176.68, up 216.17% in a year. Q2 revenue grew 44% to $335M, beating expectations. Analysts raised price targets, with Stifel at $180 and TD Cowen at $210, both maintaining Buy ratings. Positive outlook driven by healthcare advancements and strong product performance.

$GHHighAI 9/10

Guardant Health (GH) Wins FDA Approval For First Liquid Biopsy In Advanced Breast Cancer

Guardant Health (GH) received FDA approval for Guardant360 CDx, a liquid biopsy test to monitor ctDNA in advanced breast cancer. The test guides treatment decisions before disease progression, targeting about 37,000 eligible patients in the US. This approval may influence oncologist testing habits, payer coverage, and Guardant's competitive position in cancer diagnostics.

$GHHighAI 9/10

Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced Breast Cancer

Guardant Health (GH) received FDA approval for Guardant360 CDx as a companion diagnostic for AstraZeneca's ETCAMAH in advanced breast cancer. The approval, based on the SERENA-6 trial, showed a 56% reduction in disease progression risk when using ctDNA-guided treatment. The test is recommended for use every three months during therapy.

$GHHighAI 9/10

Final judgement favours TwinStrand in Guardant patent case

TwinStrand Biosciences and the University of Washington won a patent infringement case against Guardant Health, with the court awarding $245.2M in damages and royalties. The judgement upholds a jury verdict that Guardant willfully infringed two patents and must pay a 6% royalty on relevant sales until 2033. The court also affirmed the validity of the patents in question.